Evidence map›Paper›PMID 20105176›Full record

ArticleBritish journal of pharmacology2010

Deoxyelephantopin, a novel multifunctional agent, suppresses mammary tumour growth and lung metastasis and doubles survival time in mice.

Chi-Chang Huang, Chiu-Ping Lo, Chih-Yang Chiu, Lie-Fen Shyur

Abstract read
In one paragraph

Article in British journal of pharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 103 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Sesquiterpene Lactone Deoxyelephantopin Isolated fromInternational journal of molecular sciences · 2021
    Article
  16. Synergistic Cytotoxicity betweenEvidence-based complementary and alternative medicine : eCAM · 2021
    Article
  17. Synthesis of deoxyelephantopin analogues.The Journal of antibiotics · 2018
    Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Chi-Chang HuangAgricultural Biotechnology Research Center, Academia Sinica, Taipei, Taiwan.
Chiu-Ping Lo
Chih-Yang Chiu
Lie-Fen Shyur
Agricultural Biotechnology Research Center, Academia Sinica · TWNational Taiwan University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeElephantopus scaber L. (Asteraceae) is a traditional herbal medicine with anti-cancer effects. We evaluated the in vitro and in vivo efficacy of a major sesquiterpene lactone constituent of E. scaber, deoxyelephantopin (DET), against mammary adenocarcinoma and the underlying molecular mechanism. EXPERIMENTAL APPROACH: A variety of cellular assays, immunoblotting and immunohistochemistry, as well as both orthotopic and metastatic TS/A tumour models in BALB/c mice, were used. Test mice were pretreated and post-treated with DET or paclitaxel and mammary tumour growth evaluated. KEY

resultsDET (< or =2 microg x mL(-1)) significantly inhibited colony formation, cell proliferation, migration and invasion of TS/A cells and induced G(2)/M arrest and apoptosis in TS/A cells. c-Jun N-terminal kinase-mediated p21(Waf1/Cip1) expression and caspase activation cascades were up-regulated by DET, effects suppressed by N-acetyl-L-cysteine. Moreover, tumour necrosis factor alpha-induced matrix metalloproteinase-9 enzyme activity and expression and nuclear factor-kappa B activation were abolished by DET. Pretreatment with DET was more effective than paclitaxel, for profound suppression of orthotopic tumour growth (99% vs. 68% reduction in tumour size) and lung metastasis of TS/A cells (82% vs. 63% reduction in metastatic pulmonary foci) and prolonged median survival time (56 vs. 37 days, P < 0.01) in mice. The levels of cyclooxygenase-2 and vascular endothelial growth factor in metastatic lung tissues of TS/A-bearing mice were attenuated by DET. CONCLUSIONS AND IMPLICATIONS: Our data provide evidence for the suppression of mammary adenocarcinoma by DET with several mechanisms and suggest that DET has potential as a chemopreventive agent for breast cancer.

Indexed as

AdenocarcinomaAnimalsAnticarcinogenic AgentsAntineoplastic Agents, PhytogenicAntioxidantsApoptosisBreast NeoplasmsCaspasesCell CycleCell Line, TumorCell MovementCell ProliferationCyclin-Dependent Kinase Inhibitor p21Cyclooxygenase 2Dose-Response Relationship, DrugFemaleAnticarcinogenic AgentsAntineoplastic Agents, PhytogenicAntioxidantsCaspasesCDKN1A protein, humanCyclin-Dependent Kinase Inhibitor p21Cyclooxygenase 2deoxyelephantopinJNK Mitogen-Activated Protein KinasesLactonesMatrix Metalloproteinase 9NF-kappa BPaclitaxelPTGS2 protein, humanReactive Oxygen SpeciesSesquiterpenesTumor Necrosis Factor-alphaVascular Endothelial Growth Factor AVEGFA protein, human

Identifiers

PMID20105176
PMCPMC2829211
OpenAlexW1720078464

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.